Full-Time
Digital cognitive assessments for brain health
£50k - £55k/yr
Remote in UK
Remote
Remote work from the United Kingdom.
Bachelor's
See people who can refer or advise you
Cogstate provides digital cognitive assessments to support brain health research and drug development. Its tests are web- or app-based cognitive tasks that patients or trial participants complete, producing standardized scores that researchers can compare against validated benchmarks. Data from the tests is used in biopharma, academia, and clinical settings to measure cognition in trials and care, with accompanying consulting services. Unlike some competitors, Cogstate combines a long history (founded in 1999) with a focused application on cognitive measurement for pharmaceutical clinical trials and mental health/neurological conditions, along with ongoing scientific validation. The company’s goal is to improve the efficiency and reliability of cognitive measurement in research and clinical care to help develop and assess therapies for disorders like depression, schizophrenia, and bipolar disorder.
Company Size
201-500
Company Stage
IPO
Headquarters
Australia
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Generous Paid Time-off
401(k) Matching
Health, Dental & Vision Coverage
Short-Term & Long Term Disability Life Insurance
Pre-Tax Benefits
Learning & Development Opportunities
Cogstate reported record financial results for FY 2026, with revenue growing 15% year-over-year to nearly $61 million. The company's profit before tax increased 16%, while net profit after tax rose 17%. New sales contracts totalled $89 million, up 116% year-over-year. The company initiated 90 new trials during the year, compared to 35 in FY25, and is now managing 171 active clinical trials. Revenue from mood, sleep, and other neurological disorders grew 148% year-over-year, representing 30% of total revenue. Contracted future revenue reached a record $118.5 million, with $48.3 million expected to be recognised in FY27, up 54%. The company ended the year with nearly $35 million in cash and no debt. It declared a dividend of $0.04 per share, double the previous year's payout.
Cogstate, a neuroscience solutions company developing digital brain health assessments, stands out amongst Australian penny stocks with a market capitalisation of A$442 million. The company generates revenue primarily from its Clinical Trials segment at $53.59 million and Healthcare segment at $2.48 million. Cogstate demonstrates strong financial health with short-term assets exceeding liabilities and zero debt. Earnings grew 46.7% over the past year, outpacing industry averages. The company recently expanded sales contracts in Psychiatry and Narcolepsy sectors, potentially boosting future revenue. Boom Logistics, offering lifting solutions across mining and infrastructure sectors, has a market cap of A$74.16 million and generates A$275.08 million in revenue. Whilst it holds more cash than debt, forecast earnings growth stands at 20.96% annually.
Electro Optic Systems Holdings is trading at A$8.88, well below its estimated fair value of A$17.63 based on cash flows, suggesting potential undervaluation. The company develops and manufactures telescopes, laser satellite tracking systems and defence equipment, with revenue segments comprising Space (A$12.66 million) and Defence (A$115.80 million). The broader Australian market shows cautious optimism, with ASX futures indicating a 0.5% rise driven by oil and gold price movements. A screener identified 38 ASX stocks potentially trading below fair value based on cash flows, including Cogstate, whose earnings are forecast to grow 24.5% annually, significantly outpacing the Australian market's 11.9% growth rate. These opportunities emerge as investors monitor global developments, including potential Trump-Iran peace talks.
Cogstate, an ASX-listed technology company, has attracted investor attention due to its profitability and growth trajectory. Over the past three years, the company has grown earnings per share by 11% annually, whilst EBIT margins improved from 14% to 25% alongside revenue growth. The company's performance stands in contrast to loss-making speculative investments, offering a more traditional investment opportunity based on proven profitability. Cogstate's financial sustainability and consistent earnings growth demonstrate its ability to generate returns without the heightened risks associated with pre-revenue companies. Investors are also monitoring insider activity, as insider buying often signals confidence in future share price performance, though this indicator alone does not guarantee success.
New Haven, CT - August 18, 2025 - Cogstate, a leading neuroscience technology company, today announced the appointment of Luka Lucić, PhD, as Senior Director, Clinical Science, Psychiatry.